Scopus Competitors

Delisted . USA . 
Stock . Scopus Biopharma
SCPSDelisted Stock  USD 0.10  0.00  0.00%   
Scopus Biopharma competes with Scpharmaceuticals, DiaMedica Therapeutics, Monopar Therapeutics, Pasithea Therapeutics, and Protara Therapeutics; as well as few others. The company conducts business under Healthcare sector and is part of Biotechnology industry. Analyzing Scopus Biopharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Scopus Biopharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Scopus Biopharma competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.100.100.10
Details
Intrinsic
Valuation
LowRealHigh
0.100.10.10
Details
Naive
Forecast
LowNextHigh
0.050.050.05
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.090.110.13
Details

Scopus Biopharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Scopus Biopharma and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Scopus and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Scopus Biopharma does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
TARA
+ 0.82
MNPR
MGTA
+ 0.78
MTCR
STSA
+ 0.64
TARA
STSA
+ 0.62
MNPR
STSA
+ 0.57
MTCR
TARA
+ 0.56
MTCR
  
High negative correlations   
MNPR
- 0.73
SCPH
TARA
- 0.72
KTTA
KTTA
- 0.68
MNPR
STSA
- 0.65
KTTA
MTCR
- 0.64
KTTA
MGTA
- 0.58
KTTA

Risk-Adjusted Indicators

There is a big difference between Scopus OTC Stock performing well and Scopus Biopharma OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Scopus Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
SCPH  2.74 (0.62) 0.00 (0.24) 0.00 
 0.00 
 4.30 
(7.09)
 20.70 
DMAC  2.61  0.57  0.19  6.99  1.94 
(3.23)
 6.41 
(3.29)
 14.14 
MNPR  20.43  10.98  0.92 (2.33) 7.87 
(24.51)
 15.93 
(9.50)
 653.56 
KTTA  5.25 (0.30) 0.00 (0.42) 0.00 
 0.00 
 8.27 
(11.00)
 68.44 
MTCR  2.54  0.09  0.01  0.26  2.49 
(5.18)
 9.09 
(4.65)
 21.01 
MGTA  2.62  0.04  0.00  0.19  3.40 
(3.33)
 5.88 
(4.29)
 16.99 
TARA  3.34  0.69  0.18  5.54  2.72 
(4.49)
 8.67 
(4.98)
 19.48 
TCON  6.84 (2.00) 0.00 (1.51) 0.00 
 0.00 
 19.59 
(17.77)
 52.05 
STSA  3.39  0.38  0.09  0.51  3.54 
(4.82)
 5.71 
(7.79)
 70.12 
CDAKQ  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
All Fundamental Data

Scopus Biopharma Competitive Analysis

The better you understand Scopus Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Scopus Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Scopus Biopharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SCPS SCPH DMAC MNPR KTTA MTCR MGTA TARA TCON STSA
 0.00 
 0.10 
Scopus
 3.21 
 3.62 
Scpharmaceuticals
 8.64 
 5.66 
DiaMedica
 8.84 
 22.53 
Monopar
 6.55 
 3.09 
Pasithea
 0.00 
 0.49 
Metacrine
 3.80 
 0.82 
Magenta
 0.99 
 3.01 
Protara
 52.38 
 1.60 
TRACON
 0.90 
 1.10 
Satsuma
Market Volatility
(90 Days Market Risk)
Very steady
Slightly risky
Slightly risky
Out of control
Dangerous
Very steady
Very steady
Slightly risky
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Good
OK
Very Weak
Very Weak
Very Weak
Good
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Very High
Below Average
Low
Low
Dangerous
Dangerous
Below Average
Dangerous
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Not Available
Not Available
Strong Buy
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Hold
Strong Sell
Strong Sell
Not Rated
Not Rated
Cautious Hold
Not Rated
Not Rated
Current Ratio
0.31
3.72
25.5
7.61
51.17
22.29
10.22
28.94
1.17
9.18
Net Asset
8.19 M
94.48 M
54.16 M
7.35 M
26.12 M
79.99 M
146.65 M
78.95 M
10.11 M
54.94 M
Profit Margin
N/A
-2.65
N/A
N/A
N/A
N/A
N/A
N/A
0.14
N/A
EBITDA
(26.18 M)
(46.06 M)
(19.31 M)
429.04 K
(15.33 M)
(60.71 M)
(78.98 M)
(43.27 M)
(6.88 M)
(58.31 M)
Current Valuation
1.18 M
142.16 M
191.98 M
111.64 M
(8.06 M)
(23.98 M)
(32.66 M)
(14.67 M)
(2.64 M)
(35.53 M)
Price To Book
2.42
5.9
5.04
24.04
0.22
0.4
0.54
0.76
11.83
0.42
Operating Margin
N/A
-1.81
N/A
N/A
N/A
N/A
N/A
N/A
-32.12
N/A
Retained Earnings
N/A
(281.35 M)
(115.56 M)
(60.21 M)
(35.32 M)
N/A
(402.03 M)
(200.38 M)
(240.5 M)
(211.79 M)
Current Asset
N/A
N/A
5.24 M
11.55 M
N/A
N/A
33.34 M
N/A
53.31 M
N/A
Beta
1.16
0.14
1.46
1.1
0.82
-0.73
2.12
1.79
1.24
0.1
Number Of Employees
9
135
18
9
8
10
67
26
17
25
Shares Outstanding
21.09 M
50.04 M
42.76 M
5.28 M
1.27 M
42.57 M
60.66 M
20.63 M
2.68 M
33.15 M
Cash Flow From Operations
(11.42 M)
(59.24 M)
(18.73 M)
(7.86 M)
(13.43 K)
(47.16 M)
(67.09 M)
(37.56 M)
3.68 M
(51.52 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
2.54 M
40.27 M
400 K
1.76 M
81.68 K
13.3 M
29.96 M
5.47 M
968 K
205 K
Return On Equity
-15.6
-1.67
-0.35
-1.02
-0.63
-0.91
-0.65
-0.46
-12.77
-1.04
Z Score
-9.9
N/A
N/A
N/A
N/A
0.6
-3.88
N/A
N/A
99.83
Return On Asset
-4.61
-0.42
-0.24
-0.53
-0.38
-0.37
-0.29
-0.28
-0.2
-0.5
Number Of Shares Shorted
23.77 K
5.46 M
172.49 K
26.85 K
5.11 K
87.42 K
383.03 K
2.73 M
166.13 K
130.12 K
Book Value Per Share
-0.26
1.03
1.35
1.88
22.46
0.87
1.24
6.01
-0.66
1.14
Current Liabilities
N/A
N/A
1.05 M
598.26 K
N/A
N/A
3.39 M
N/A
14.18 M
N/A
Total Asset
8.19 M
94.48 M
54.16 M
7.35 M
26.12 M
79.99 M
146.65 M
78.95 M
10.11 M
54.94 M
Debt To Equity
0.61
0.32
N/A
0.002
0.008
0.33
0.25
0.046
0.35
0.002
Short Ratio
0.22
12.92
3.88
0.15
0.32
0.21
1.38
14.46
0.95
0.05
Target Price
12.0
18.0
7.0
27.33
2.0
0.5
1.0
29.5
30.5
2.0
Shares Owned By Institutions
2.15
81.67
31.61
24.47
2.86
35.96
62.63
51.1
11.42
57.9
Market Capitalization
2.17 M
187.15 M
241.81 M
118.91 M
3.91 M
20.94 M
45.14 M
62.71 M
3.83 M
36.8 M
Price To Earning
N/A
N/A
-3.52
-35.82
N/A
N/A
-1.63
N/A
-1.51
22.12
Price To Earnings To Growth
N/A
N/A
-0.07
N/A
N/A
N/A
N/A
N/A
N/A
4.5
Price To Sales
N/A
6.18
N/A
N/A
42.15
N/A
N/A
N/A
0.45
N/A
Net Income
(26.95 M)
(54.81 M)
(19.38 M)
(8.4 M)
(15.51 M)
(62.21 M)
(76.46 M)
(40.42 M)
(3.59 M)
(70.06 M)
Earnings Per Share
-1.51
-1.95
-0.56
-1.98
-14.79
-1.93
-1.11
-2.64
106.4
-1.99
Shares Owned By Insiders
50.66
10.67
26.22
42.94
23.12
12.29
2.23
6.12
2.2
10.43
Revenue
N/A
13.59 M
N/A
N/A
486.56 K
N/A
N/A
N/A
12.04 M
N/A
Working Capital
N/A
79.8 M
50.89 M
5.58 M
14.06 M
N/A
101.05 M
62.56 M
(1.09 M)
46.69 M
Cash And Equivalents
1.16 M
55.85 M
38.44 M
16.46 M
47.94 M
55.53 M
128.28 M
98.46 M
13.58 M
68.06 M
Cash Per Share
0.05
2.04
1.45
1.29
1.8
1.3
2.13
8.74
0.63
2.15
Gross Profit
N/A
N/A
N/A
N/A
(2.21 K)
(45.47 M)
N/A
N/A
(13.89 M)
N/A
Day Typical Price
0.1
3.66
5.51
21.8
3.04
0.48
0.81
3.06
1.39
1.08
Accumulation Distribution
0.0909
0.0605
0.0795
0.14
0.0518
0.17
0.0482
0.1
0.5
0.11
Market Facilitation Index
0.01
0.23
0.45
3.13
0.16
0.09
0.04
0.34
0.86
0.13
Daily Balance Of Power
N/A
(0.52)
1.0
0.5847
1.1875
N/A
0.75
(0.09)
0.6395
(0.08)
Period Momentum Indicator
N/A
(0.12)
0.45
1.83
0.19
N/A
0.03
(0.03)
0.55
(0.01)
Rate Of Daily Change
1.0
0.97
1.09
1.09
1.07
1.0
1.04
0.99
1.52
0.99
Day Median Price
0.11
3.68
5.44
21.44
3.01
0.48
0.81
3.08
1.28
1.08
Price Action Indicator
(0.01)
(0.12)
0.45
2.01
0.17
0.015
0.025
(0.09)
0.6
0.02
Relative Strength Index
47.48
47.49
44.63
58.68
30.64
50.69
68.65
69.55
17.46
60.84
Coefficient Of Variation
7219.48
(920.20)
578.41
722.78
(4,250)
2186.22
2966.12
597.56
(610.48)
1667.7
Mean Deviation
12.15
2.74
2.61
20.43
5.25
2.54
2.62
3.34
6.84
3.39
Jensen Alpha
0.2071
(0.62)
0.5656
10.98
(0.30)
0.0887
0.0381
0.6906
(2.00)
0.378
Total Risk Alpha
(2.90)
(1.02)
0.0102
(2.16)
(1.78)
(0.49)
(0.50)
(0.01)
(3.72)
(0.93)
Sortino Ratio
0.0058
N/A
0.1947
0.9164
N/A
0.0121
(0)
0.181
N/A
0.0914
Downside Variance
458.22
N/A
5.31
125.98
N/A
13.71
17.78
10.24
N/A
16.97
Standard Deviation
18.88
3.65
3.39
75.34
9.27
3.99
3.69
4.28
11.21
8.57
Kurtosis
2.75
1.94
1.78
62.49
15.62
5.11
3.46
0.6816
5.52
46.63
Potential Upside
35.42
4.3
6.41
15.93
8.27
9.09
5.88
8.67
19.59
5.71
Treynor Ratio
0.7214
(0.24)
6.99
(2.33)
(0.42)
0.2631
0.1912
5.54
(1.51)
0.5106
Maximum Drawdown
94.02
20.7
14.14
653.56
68.44
21.01
16.99
19.48
52.05
70.12
Variance
356.59
13.31
11.49
5676.2
85.91
15.88
13.63
18.35
125.56
73.46
Market Risk Adjusted Performance
0.7314
(0.23)
7.0
(2.32)
(0.41)
0.2731
0.2012
5.55
(1.50)
0.5206
Risk Adjusted Performance
0.0202
(0.08)
0.1399
0.1157
(0.01)
0.043
0.0337
0.1361
(0.12)
0.0549
Skewness
0.266
(0.87)
1.18
7.81
3.0
1.59
(0.42)
0.8182
(0.27)
6.24
Semi Deviation
16.66
N/A
1.94
7.87
N/A
2.49
3.4
2.72
N/A
3.54
Information Ratio
0.0066
(0.15)
0.1323
0.1365
(0.04)
0.0112
(0)
0.1352
(0.18)
0.0439
Value At Risk
(24.69)
(7.09)
(3.29)
(9.50)
(11.00)
(4.65)
(4.29)
(4.98)
(17.77)
(7.79)
Expected Short fall
(15.32)
N/A
(3.23)
(24.51)
N/A
(5.18)
(3.33)
(4.49)
N/A
(4.82)
Downside Deviation
21.41
N/A
2.3
11.22
N/A
3.7
4.22
3.2
N/A
4.12
Semi Variance
277.44
N/A
3.77
62.0
N/A
6.19
11.57
7.43
N/A
12.53

Scopus Biopharma Competition Performance Charts

Five steps to successful analysis of Scopus Biopharma Competition

Scopus Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Scopus Biopharma in relation to its competition. Scopus Biopharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Scopus Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Scopus Biopharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Scopus Biopharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Scopus Biopharma position

In addition to having Scopus Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Health Care ETFs Thematic Idea Now

Health Care ETFs
Health Care ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Health Care ETFs theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Care ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in Scopus OTC Stock

If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY